Metabolic therapies such as GLP-1s primarily influence inflammation, mitochondrial function, and nutrient signaling, while other pharmacological or lifestyle strategies may act on telomere maintenance [16], senescence biology [17], or epigenetic regulation [18]
Chemiluminescence signals were measured at 620 and 650 nm by an EnVision plate reader (PerkinElmer)
As a result, the FDA required black box warnings on some GLP-1 medications
Days later, the agency reversed course, acknowledging the shortage still existed
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dys-function-associated steatotic liver disease (MASLD)
Professional medical societies actively engage in developing clinical practice guidelines and treatment quality standards